tbuckley/cabot-search huggingface dataset:
Abstract 5243: CRISPR knockout: How to get high biallelic knockout
Authors: Yongqi Li, Li Min, Ellen Liu, Yiran Wang
Journal: Cancer Research (2019)

Abstract Although homology directed repair (HDR)-mediated gene knockout / knockin is well established, it cannot necessarily be applied in some cell types and organisms with low HDR frequencies. Herein we describe an improved technology for genome-wide gene knockout / knockin using CRISPR-Cas9 targeted genome editing: CRISPR KN2.0. CRISPR KN2.0 technology is specifically designed to provide an easy-to-use and get around 50% biallelic knockout. This gene knockout / knockin technology is designed to knock out any DNA locus and knock in a functional cassette containing Green Fluorescence Protein (GFP) and puromycin resistant gene to facilitate screening process. Both of these cassettes are expressed under EF1A promoter after genomic integration. CRISPR KN 2.0 has been used to successfully knock out many genes / knocked in functional cassette in HeLa, HEK293T and MIA PaCa-2 (a human pancreatic carcinoma cell line) cells. Studies carried out in house and by some colleagues show that CRISPR KN 2.0 is highly efficient and render improved knockout/knockin rate (over 50% positively integrated colonies after puromycin selection). Citation Format: Yongqi Li, Li Min, Ellen Liu, Yiran Wang. CRISPR knockout: How to get high biallelic knockout [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5243.
Mission: Possible
Authors: Robert H. Moser
Journal: JAMA (1973)

For weeks I have been pondering the ideas and words of this, my maiden voyage on the editorial pages of<i>JAMA</i>. I have felt the redolence of my predecessors. I am sensitive to the responsibility of editing a journal that is seen by more professional eyes than any other medical publication in the world. True, I come as a novice editor—but I am a veteran reader. At different times I have also been a clinical teacher, a medical soldier, a department head, and a practicing internist. From each of these vantage points I learned that I needed something a little different from my reading. It is from this "eclectic" aspect that I derived the concept of what I want for<i>JAMA</i>. Its guiding principle will be to educate the practitioner. There is a simple dialectic involved in this conception of mission, and it goes something like this: All of us
The Ophthalmopathy Of Graves' Disease
Authors: J. Carter
Journal: Annual Review of Medicine (1992)

Ophthalmopathy is an integral component of Graves' disease. It usually appears at the same time as hyperthyroidism, and is characterized by proptosis (exophthalmos), periorbital and conjunctival edema, eye muscle dysfunction, and on occasion corneal ulceration or optic neuropathy. Graves' ophthalmopathy, like Graves' hyperthyroidism, is an autoimmune disease, but the mechanisms that initiate and maintain it are not known. Most patients can be treated conservatively, but a few require antiinflammatory or surgical therapy to relieve symptomsa nd preserve vision.
Abstract 109: Predictors Of Unresponsiveness To Initial Immunoglobulin In Patients With Kawasaki Disease
Authors: Jeong Jin Yu, Eun Kyung Cho, Hyun Ok Jun, So Yeon Kang, Chang Deok Seo, Jae Suk Baek, Young-Hwue Kim, Jae-Kon Ko
Journal: Circulation (2015)

Background: Recently, several studies to predict the unresponsiveness to initial intravenous immunoglobulin (IVIG) treatment during the acute phase of Kawasaki disease have been conducted. However, reported predictors are varied in those studies. The racial difference was assumed as the cause of such diversity. The aim of this study is to find predictors of unresponsiveness to initial IVIG in Korean children with Kawasaki disease. Subjects and methods: Subjects were 424 patients with Kawasaki disease who had been admitted to Asan Medical Center from January 2006 to December 2012. Demographic, clinical, and laboratory data were investigated through a review of medical records. Laboratory data before initial IVIG treatment and within 10 days after fever onset were selected. Forty one patients (9.7%) were non responders to initial IVIG treatment. Univariate and multivariate logistic regression analyses were performed to find predictors of unresponsiveness to initial IVIG treatment. Results: Median age was 30.0 months (range 1.6-186.0 months) in IVIG-responders, and 30.9 months (range 2.9-107.8 months) in IVIG-nonresponders (P=0.819). Number of females was 156 (40.7%) and 15 (36.6%) respectively (P=0.607). No other demographic and clinical variables were different between two groups. Univariate analyses showed that neutrophil percentage (P&lt;0.001), serum C-reactive protein (P=0.008) and total bilirubin (P&lt;0.001) were higher, and that serum protein level (P=0.001), albumin level (P&lt;0.001), sodium concentration (P&lt;0.001), and chloride concentration (P=0.002) were lower in IVIG-nonresponders. Neutrophil percentage (OR 1.075, 95% confidence interval 1.027~1.125. P=0.002) and serum total bilirubin(OR 1.845, 95% interval 1.284~2.650. P=0.001) were significant predictors in Multivariate analyses. Conclusion: The results of this study were inconsistent with the results of previously conducted studies with the same purpose in other countries. Therefore future study with more number of subjects is needed for confirmative identification of predictors of unresponsiveness to initial IVIG treatment in patients with Kawasaki disease.
A VETO ON PROPHYLAXIS FOR OPHTHALMIA NEONATORUM
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MENINGOCOCCUS TOXIN
Authors: N. S. Ferry
Journal: JAMA (1935)

<h3>To the Editor:—</h3> The article entitled "Active Immunization with Meningococcus Toxin" by Ferry and Steele, published in The Journal, March 23, has provoked requests for this toxin to be used for active immunization against meningococcic meningitis. It was not the intention of the authors to convey the impression that this toxin is available for distribution or that proof of active protection against the disease had been established. In fact, in the body of the paper the latter phase of the problem is covered in the statement "While the results of these tests indicate certain facts in regard to the stimulation of active immunity in man against meningococcus toxin, they do not necessarily signify that an immunity against the organism can be produced at the same time."
<i>Withdrawn:</i> Does the gene matter? Genotype‐phenotype and genotype‐outcome associations in congenital melanocytic naevi
Authors: S. Polubothu, N. McGuire, L. Al‐Olabi, W. Baird, N. Bulstrode, J. Chalker, D. Josifova, D. Lomas, J. O'Hara, J. Ong, D. Rampling, P. Stadnik, A. Thomas, E. Wedgeworth, N.J. Sebire, V.A. Kinsler
Journal: British Journal of Dermatology (2020)

DOI: 10.1111/bjd.19296 S. Polubothu N. McGuire L. Al‐Olabi et al. Does the gene matter? Genotype‐phenotype and genotype‐outcome associations in congenital melanocytic naevi. https://onlinelibrary.wiley.com/doi/10.1111/bjd.18747 https://onlinelibrary.wiley.com/doi/10.1111/bjd.18762 (Mandarin) The above Plain Language Summary from the British Journal of Dermatology, published online on 03 February 2020 in Wiley Online Library (wileyonlinelibrary.com), and in print and online in issue 182.2, also translated into Mandarin in issue 182.2, has been withdrawn by agreement between the authors, the journal's editor‐in‐chief, John Ingram, the British Association of Dermatologists, and John Wiley & Sons Limited. Both the original Plain Language Summary and the Mandarin translation of the Plain Language Summary have been withdrawn. The Plain Language Summary incorrectly attributed authorship to the authors of the original article S. Polubothu N. McGuire L. Al‐Olabi, et al. The Plain Language Summary was written by a BJD in‐house dermatologist and not the authors. The authors of the original article were inserted to establish a link to the paper, and not to attribute authorship of the Plain Language Summary. The Plain Language Summary has now been withdrawn and replaced with a version provided by the authors. We apologise for this error, and have since changed the way our Plain Language Summaries are written and attributed.
In-vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel.
Authors: Doron Feinsilber, Cliff Whatcott, Marc Ryan Matrana, Jyotsna Fuloria, Suma Satti, John T. Cole, Qingyang Luo, Ruben Munoz
Journal: Journal of Clinical Oncology (2015)

e15245 Background: Statins have been shown to possess antiproliferative activity in-vitro. Synergism with multiple drug combinations has been a topic of great interest in pancreatic cancer. We examined 2 in-vitro cell models for synergism using a combination of fluvastatin and nab-paclitaxel. Methods: Pancreatic cancer cell lines Mia-Paca-2 (MP2) and Su86 were cultivated and seeded to 25000 cells/mL and subsequently grown in 96 well plates for 24 hours. The cells were then treated with a fixed concentration of fluvastatin in 9 rows, 8 receiving serial 1:2 dilutions 16 times intriplicate of nab-paclitaxel, 1 fluvastatin only row , and 1 untreated. Upon dosing cells were incubated for 72 hrs. Cellular proliferation was determined by sulforhodamine B proliferation assays and read at 570 nm. A nab-paclitaxel only assay was done as well for comparison. The drug dose response (DDR) curves of nab-paclitaxel with fluvastatin were then compared for synergism. Results: The lowest inhibitory concentrations of fluvastatin in combination with nab-paclitaxel was noted to be between 500 to 600 micromolar. Fluvastatin alone at these concentrations attenuated cellular proliferation among both Mia-Paca-2 (MP2) and Su86 cell lines. This is indicative of a moderate synergism observed when these concentrations have been added to nab-paclitaxel. Data curves available. Conclusions: Fluvastatin has an in-vitro anti proliferative effect on Su86 and Mia-paca-2 (MP2) cells when treated with monotherapy. Fluvastatin has displayed moderate synergism among both cell lines in combination with nab-paclitaxel. Fluvastatin was shown to be more cytotoxic in Su86 but has a higher degree of synergism with Mia-Paca-2 (MP2) cell lines. Mouse models are next being investigated. A pilot phase 2 randomized controlled trial (RCT) is currently being designed to evaluate efficacy of fluvastatin and nab-paclitaxel in patients who have failed gemcitabine/nab-paclitaxal therapy previously. Selection criteria to be discussed.
Identification of a panel of safe immunogenic antigens for therapeutic vaccination strategies in hepatocellular carcinoma
Authors: Lisanne Noordam, Zhouhong Ge, Hadiye Öztürk, Shanta Mancham, Michael Doukas, Patrick Boor, Guoying Zhou, Isabel Vögler, Qiuwei Pan, Jan IJzermans, Marco J. Bruno, Dave Sprengers, Jaap Kwekkeboom
Journal: Journal of Hepatology (2020)
Die Digitalisbehandlung
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fast-Track Surgical Referral in a Population Displaced by War and Conflict
Authors: J M Ryan, Matthew Fleggson, John Beavis, Cara Macnab
Journal: Journal of the Royal Society of Medicine (2003)

After the 1988–1994 conflict between Armenia and Azerbaijan, fought over the territory of Nagorno-Karabakh, large numbers of people were resettled in camps in southern Azerbaijan. Healthcare in the camps was generally good but there was no access to hospitals. The Leonard Cheshire Centre of Conflict Recovery (LCC) organized a ‘fast-track’ system of surgical care in the southern camps by securing the help of still-functioning hospitals in the distant capital, Baku. Regular clinics were held in the camps for visiting specialists; and, by arrangement with the Government of Azerbaijan and various non-governmental organizations, treatment was offered to those who fell within strict selection criteria. After a pilot study yielded clear benefits, the scheme was transferred to a local nongovernmental organization, which successfully operated an expanded version. The hidden cost of war often includes the neglect of chronic medical conditions that require secondary and tertiary care. The ‘fast-track’ system illustrates the potential of existing facilities to meet these needs at modest cost, given sufficient support.
Erythropoietin assay and ferrokinetic measurements in anemic uremic patients
Authors: D. L. Mann
Journal: JAMA (1965)

INVESTIGATION of humoral regulation of erythropoiesis has broadened insight into various clinical disorders of red blood cell (RBC) production.<sup>1,2</sup>Significant observations<sup>3</sup>have clarified, in part, the pathogenesis of the erythroid failure associated with chronic renal insufficiency. Nonetheless, the complete explanation for this apparently unique abnormality remains uncertain. In the present study, ferrokinetic measurements and plasma erythropoietin assays were undertaken in eight anemic uremic patients before and after the amelioration of the uremic state by peritoneal dialysis. <h3>Methods and Results</h3> Clinical data are presented in Table 1. Hematocrit readings, hemoglobin levels, reticulocyte counts,<sup>4</sup>blood urea nitrogen (BUN), and serum creatinine levels were determined prior to and following peritoneal dialysis. Dialysis was performed by the intraperitoneal method<sup>5</sup>with a commercially available dialysing solution (Peridial) to which 4 mEq of potassium chloride per liter was added. A course of peritoneal dialysis consisted of an exchange of an average of 42
High ambient pressure produces hypertrophy and up-regulates cardiac sarcoplasmic reticulum Ca2+ regulatory proteins in neonatal rat cardiomyocytes Tomoko Ohkusa, Masafumki Yano, Reo Mitani, Jutaro Yamada, Tomoko Nao, Shigeki Kobayashi, Masunori Matsuzaki. The Second Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan
Journal: Journal of the American College of Cardiology (2001)
Radioactive isotopes in clinical medicine. II.
Authors: C. W. Havard, J. McAlister
Journal: BMJ (1967)

Studies of Absorption and Distribution Iron AbsorptionFerrous iron is absorbed from the duodenum and upper part of the small intestine in quantities that depend on the body needs.Thus as the iron stores fall more iron is absorbed.Ferric iron must be reduced to the ferrous state before it can be absorbed, and ascorbic acid, among other reducing agents, will achieve this.Iron is not absorbed by diffusion but by a specific carrier protein within the intestinal cell called apo- ferritin, which binds the ferrous iron into a protein complex, "ferritin," in which the iron is in ferric form.This apo- ferritin-ferritin cycle regulates iron absorption and prevents iron overloading, for, once absorbed, iron cannot be excreted in appreciable amounts.After absorption iron becomes attached to a beta-globulin called transferrin, and is cleared quickly from the plasma by the bone marrow, where it is incorporated into the haemoglobin molecule of the developing erythrocyte.The total serum-iron level remains at about 120 jtg.per 100 ml., and transferrin is normally only one-third saturated.Iron excreted in the faeces represents the amount unabsorbed, and a measure of the fraction absorbed may therefore be obtained from the difference between the amount in the faeces and the dose given by mouth.Normally the amount of iron absorbed is not more than 30%, but in iron deficiency this figure may increase to 80%.Seventy to one hundred per cent. of the absorbed iron will reappear in the circulating erythrocytes within a period of ten days.The remainder is deposited as iron stores in the form of ferritin or haemosiderip in the liver, spleen, bone marrow, and reticulo-endothelial system.-Studies of the absorption of radioactive inorganic iron salts in a fasting subject give information of only limited value, for ferrous salts are absorbed more readily than food iron in both normal people and patients with iron deficiency.Indeed, in patients who have undergone partial gastrectomy food iron may be absorbed poorly but ferrous chloride readily.The difference is due in part to the necessity of reducing the food iron to the ferrous form before absorption takes place, and in part to the solid content of the test meal and the formation of insoluble iron compounds, such as phytates and phosphates, when the iron is taken in food.In order to study iron absorption under natural conditions, the absorption of iron incorporated biosynthetically into foods, such as eggs and vegetables, may be studied, but the labelling process is tedious.Tests of iron absorption have therefore been developed in which the labelled iron is added to a meal of standard iron content.Though this is not an exact reproduction of the conditions by which food iron is absorbed, it has been shown to provide a reliable measure of absorption of dietary iron.
The Risk of Contracting HIV Infection in the Course of Health Care
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection*1
Authors: C FERRY
Journal: Hepatology (1995)

The aim of this open trial was to assess the efficacy and the safety of interferon (IFN) alfa therapy in liver transplant recipients with chronic active hepatitis caused by hepatitis C virus. In July 1991, among 447 liver recipients regularly observed at our institution, 46 had developed HCV-related chronic active hepatitis defined by piece meal necrosis. Fourteen of these 46 patients received IFN alfa 3 mIU three times weekly for a planned duration of 6 months and were compared to the 32 untreated patients. Genotyping and quantification of viremia were performed using type-specific amplification and branched DNA assay. Histological follow-up was available in all patients and routinely before and after IFN therapy. Treated and untreated patients did not differ regarding gender, age, length of follow-up, maximum histological score, and genotypes (41 of 46 were of type lb). Induction of chronic rejection was observed in 5 of 14 treated patients leading to retransplantation in 3. In contrast, chronic rejection occurred in 1 of 32 untreated patients (P < .005) during the posttransplantation follow-up. Among the 9 treated patients without rejection, a decrease of transaminases or of HCV RNA levels of more than 50% were observed in 8 and 4, respectively; 2 patients had a complete response, and 1 did not relapse after discontinuation of IFN. Histological improvement occurred in 2 of the treated patients and in none of the untreated patients. IFN therapy in liver transplant recipients has poor antiviral effect and can induce chronic rejection. Its use in this setting should be cautious.
Rebuttal
Authors: Delphis C. Goldberg
Journal: JAMA (1975)

THE preceding commentary by Drs. Louis Lasagna and William M. Wardell presents a distorted and unfair representation of hearings held earlier this year by the House Intergovernmental Relations Subcommittee. Lasagna and Wardell state that at hearings in the House of Representatives chaired by Congressman Fountain, "FDA officials have been reprimanded for being 'soft' on industry and too ready to approve new drugs." They cite the hearing on the Food and Drug Administration (FDA) approval of propranolol for the relief of angina pectoris as a case in point, noting that cardiologists have for years accepted and used this drug in the management of severe angina. First, I must state unequivocally that the Subcommittee hearing record does not support in any way the contention that FDA officials were reprimanded for being "soft" on industry. This is untrue. With respect to the approval of propranolol for angina, the Subcommittee was concerned solely and